WO2001056592A1 - Use of compounds for the regulation of food intake - Google Patents

Use of compounds for the regulation of food intake Download PDF

Info

Publication number
WO2001056592A1
WO2001056592A1 PCT/DK2001/000064 DK0100064W WO0156592A1 WO 2001056592 A1 WO2001056592 A1 WO 2001056592A1 DK 0100064 W DK0100064 W DK 0100064W WO 0156592 A1 WO0156592 A1 WO 0156592A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
medicament
pharmaceutically acceptable
manufacture
treatment
Prior art date
Application number
PCT/DK2001/000064
Other languages
French (fr)
Inventor
Maibritt Bansholm Andersen
Birgit Sehested Hansen
Kirsten Raun
Søren TULLIN
Lars Thim
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Priority to AU2001228325A priority Critical patent/AU2001228325A1/en
Publication of WO2001056592A1 publication Critical patent/WO2001056592A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Definitions

  • the present invention relates to the use of a compound that is a ligand for the receptor GHS-R 1 A for the regulation of food intake.
  • the present invention also embraces pharmaceutical compositions comprising these compounds and methods of using the compounds and their pharmaceutical compositions.
  • Stimulation of food intake is important in connection with patients suffering from anorexia due to chronic medical conditions, eating disorders, and other conditions in which excessive weight loss has produced a detrimental effect on the patients' health.
  • Obesity is a well-known risk factor for the development of many very common diseases such as atherosclerosis, hypertension, Type II diabetes (non-insulin dependent diabetes mellitus (NIDDM)), dyslipi- daemia, coronary heart disease, and osteoarthritis and various malignancies. It also causes considerable problems through reduced mobility and decreased quality of life. The incidence of obesity and thereby also these diseases is increasing throughout the entire industrialised world. Except for exercise, diet and food restriction, no convincing treatment for reducing body weight effectively and acceptably currently exist. However, due to the important effect of obesity as a risk factor in serious and even fatal and common dis- eases, it will be important to find pharmaceutical compounds useful in prevention and treatment of obesity.
  • NIDDM non-insulin dependent diabetes mellitus
  • compositions that can be used for the regulation of food intake are provided.
  • a further object is to provide compositions that can be used for the treatment of anorexia.
  • a still further object is to provide compositions that can be used for the treatment of excessive weight loss.
  • a further object is to provide compositions that can be used for the treatment of obesity.
  • a still further object is to provide compositions that can be used for the treatment of type II diabetes.
  • Yet another object of the invention is to provide compositions useful in the treatment of wasting, which frequently accompanies ageing as well as various diseases and medical conditions.
  • the present invention relates, inter alia, to the use of a compound that is a ligand for the receptor GHS-R 1 A, or pharmaceutically acceptable salts thereof, for the manufacture of a medicament for the regulation of food intake.
  • the present invention provides the use of a compound that is a ligand for the receptor GHS-R 1A, or pharmaceutically acceptable salts thereof, for the manufacture of a medicament for the regulation of food intake.
  • a further aspect of the present invention relates to a method for the regulation of food intake, which method comprises administering an effective amount of a compound that is a ligand for the receptor GHS-R 1 A, or pharmaceutically acceptable salts thereof, to a patient in need of such a treatment.
  • a still further aspect of the present invention relates to the use of a compound that is a ligand for the receptor GHS-R 1 A, or pharmaceutically acceptable salts thereof, for the manufacture of a medicament for the regulation of Body Mass Index (BMI).
  • BMI Body Mass Index
  • a further aspect of the present invention relates to the use of a compound that is a ligand for the receptor GHS-R 1 A, or pharmaceutically acceptable salts thereof, for the manufacture of a medicament for the treatment of anorexia.
  • a still further aspect of the present invention relates to the use of a compound that is a ligand for the receptor GHS-R 1A, or pharmaceutically acceptable salts thereof, for the manufacture of a medicament for the treatment of lack of appetite in children with a growth hormone deficiency.
  • a further aspect of the present invention relates to the use of a compound that is a ligand for the receptor GHS-R 1A, or pharmaceutically acceptable salts thereof, for the manufacture of a medicament for the treatment of obesity.
  • a still further aspect of the present invention relates to the use of a compound that is a ligand for the receptor GHS-R 1 A, or pharmaceutically acceptable salts thereof, for the manufacture of a medicament for the treatment of Type II diabetes.
  • a further aspect of the present invention relates to the use of a compound that is a ligand for the receptor GHS-R 1A, or pharmaceutically acceptable salts thereof, for the manufacture of a medicament for the treatment of wasting associated with various diseases or conditions, e.g. wasting associated with AIDS, chronic liver disease, chronic obstructive pulmonary disease (COPD) or respiratory insufficiency in general, as well as wasting associated with bone fractures or with ageing.
  • wasting associated with various diseases or conditions e.g. wasting associated with AIDS, chronic liver disease, chronic obstructive pulmonary disease (COPD) or respiratory insufficiency in general, as well as wasting associated with bone fractures or with ageing.
  • COPD chronic obstructive pulmonary disease
  • Wasting which involves a progressive loss of body mass, including muscle mass, is normally attributable to a catabolic state of metabolism, and is frequently difficult to reverse by purely dietary means.
  • the receptor GHS-R 1A is the human GHS-R 1A receptor.
  • the medicament is for humans.
  • the compound does not induce a therapeutically effective growth hormone release at the therapeutic dose of the compound.
  • the medicament is a non-injectable medicament.
  • the medicament is an oral medicament.
  • the receptor GHS-R 1 A (the growth hormone secretagogue receptor type 1 A) is described by Howard, A. D. et al. (1996) in Science 273, 974-977.
  • the binding of a compound to the receptor GHS-R 1A can, e.g., be measured by the use of the assays as described in Example 1 herein.
  • the ligand has a potency (EC 50 ) on the GHS-R 1A of less than 500 nM. In another embodiment the ligand has a potency (EC 50 ) on the GHS-R 1A of less than 100 nM.
  • the binding constant (K D ) of the ligand is less than 500 nM. In a still further embodiment the binding constant (K D ) of the ligand is less than 100 nM.
  • the ligand is an agonist for the receptor GHS- R 1A. In another embodiment of the invention the ligand is an antagonist for the receptor GHS-R 1A.
  • the compound employed in accordance with the invention is adenosine.
  • the compound is ghrelin or a peptide homologous thereto. Ghrelin is described by Kojima in Nature (1999), vol. 402, 656-660.
  • Peptides homologous to ghrelin are peptides which have an amino acid sequence which has a degree of identity to ghrelin of at least about 70%, preferably at least about 80%, more preferably at least about 90%, even more preferably at least about 95%, and most preferably at least about 97%, and which qualitatively retain the activity as a ligand for the receptor GHS-R 1A.
  • the degree of identity between two or more amino acid sequences may be determined by means of computer programs known in the art, such as GAP provided in the GCG program package (Needleman and Wunsch, 1970, Journal of Molecular Biology 48:443-453). For the purposes of determining the degree of identity between two amino acid sequences for the present invention, GAP is used with the following settings: GAP creation penalty of 3.0 and GAP extension penalty of 0.1.
  • a therapeutically effective growth hormone release is to be understood as a growth hormone release which would have a therapeutic effect in treatment of the specific indication, e.g. regulation of food intake.
  • the therapeutic dose of the compound will depend upon the frequency and mode of administration, the sex, age, weight and general condition of the subject treated, the nature and severity of the condition treated and any concomitant diseases to be treated, and other factors evident to those skilled in the art.
  • the effective amount of the compound is in the range from about 0.05 to about 2000 mg, preferably from about 0,1 mg to about 1000 mg, and especially from about 0.5 to about 500 mg per day.
  • BMI Body Mass Index
  • the present invention also encompasses pharmaceutically acceptable salts of the present compounds.
  • Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable metal salts, ammonium salts and alkylated ammonium salts.
  • Acid addition salts include salts of inorganic acids as well as organic acids. Representative examples of suitable inorganic acids include hydrochloric, hydrobromic, hydriodic, phosphoric, sulpfuric and nitric acids and the like.
  • suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methanesulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, ethylenediaminetetraacetic (EDTA), p-aminobenzoic, glutamic, benzenesulfonic and p- toluenesulfonic acids and the like.
  • EDTA ethylenediaminetetraacetic
  • compositions include the pharmaceutically acceptable salts listed in J. Pharm. Sci. 1977, 66, 2, which is incorporated herein by reference.
  • metal salts include lithium, sodium, potassium and magnesium salts and the like.
  • ammonium and alkylated ammonium salts include ammonium, methylammonium, dimethylammonium, trimethylammonium, ethylammonium, hydroxyethylammonium, diethylammonium, butylammonium and tetramethylammonium salts and the like.
  • a "ligand for the receptor GHS-R 1A” is understood to refer to any compound which has affinity to the receptor GHS-R 1 A as measured by the method as described in Example 1 herein.
  • treatment is to be understood as treatment and/or prevention.
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising, as an active ingredient, a compound as defined above or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier.
  • the present compounds may be administered in combination with further pharmacologically active substances, e.g. an antidiabetic agent or other pharmacologically active material, including other compounds for the treatment and/or prevention of insulin resistance and diseases wherein insulin resistance is the pathophysiological mechanism.
  • pharmacologically active substances e.g. an antidiabetic agent or other pharmacologically active material, including other compounds for the treatment and/or prevention of insulin resistance and diseases wherein insulin resistance is the pathophysiological mechanism.
  • a still further aspect of the present invention is a method of identifying compounds for the regulation of food intake, characterised by screening out compounds that act as ligands for the receptor GHS-R 1 A.
  • a further aspect of the present invention relates to a compound identified by or identifiable by this method.
  • the compounds of the invention may be administered alone or in combination with pharmaceutically acceptable carriers or excipients, in either single or multiple doses.
  • the pharmaceutical compositions according to the invention may be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 19 th Edition, Gennaro, Ed., Mack
  • compositions may be specifically formulated for administration by any suitable route such as the oral, rectal, nasal, pulmonary, topical (including buccal and sublingual), transdermal, intracisternal, intraperitoneal, vaginal and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous and intradermal) route, the oral route being preferred. It will be appreciated that the choice of route will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated and the active ingredient chosen.
  • compositions for oral administration include solid dosage forms such as capsules, tablets, dragees, pills, lozenges, powders and granules. Where appropriate, they can be prepared with coatings, such as enteric coatings, or they can be formulated so as to provide controlled release of the active ingredient, such as sustained or prolonged release according to methods well known in the art.
  • Liquid dosage forms for oral administration include solutions, emulsions, suspensions, syrups and elixirs.
  • compositions for parenteral administration include sterile aqueous and non-aqueous injectable solutions, dispersions, suspensions or emulsions, as well as ster- ile powders to be reconstituted in sterile injectable solutions or dispersions prior to use. Depot injectable formulations are also contemplated as being within the scope of the present invention.
  • Suitable administration forms include suppositories, sprays, ointments, cremes, gels, inhalants, dermal patches, implants etc.
  • a typical oral dosage of a compound employed according to the invention is in the range of from about 0.0001 to about 100 mg/kg body weight per day, preferably from about 0.001 to about 10 mg/kg body weight per day, and more preferably from about 0.01 to about 1 mg/kg body weight per day, administered in one or more doses, such as 1 to 3 doses.
  • a typical unit dosage form for oral administration one or more times per day, such as 1 to 3 times per day, may contain from about 0.05 to about 2000 mg, preferably from about 0.1 to about 500 mg, and more preferably from about 0.5 mg to about 200 mg of a compound employed according to the invention.
  • doses are typically of the order of about half the dose employed for oral administration.
  • the compounds of this invention are generally utilized as the free substance or as a phar- maceutically acceptable salt thereof.
  • One example is an acid addition salt of a compound having a free base functionality.
  • a compound of the invention contains a free base functionality
  • such salts are suitably prepared in a conventional manner by treating a solution or suspension of the free base form of the compound with, typically, one equivalent (chemical equivalent, i.e. acid-base equivalent) of a pharmaceutically acceptable acid, for example an inorganic or organic acid chosen among the representative examples thereof mentioned above.
  • Physiologically acceptable salts of a compound with a hydroxy group include the anion of said compound in combination with a suitable cation, such as sodium or ammonium ion.
  • solutions of the present compounds in sterile aqueous solution aqueous propylene glycol or sesame or peanut oil may be employed.
  • aqueous solutions should be suitably buffered if necessary, and the liquid diluent first rendered iso- tonic with sufficient saline or glucose.
  • the aqueous solutions are particularly suitable for in- travenous, intramuscular, subcutaneous and intraperitoneal administration.
  • the sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.
  • Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solution and various organic solvents.
  • solid carriers are lactose, terra alba, sucrose, cyclodextrin, talc, gelatine, agar, pectin, acacia, magnesium stearate, stearic acid or lower alkyl ethers of cellulose.
  • liquid carriers are syrup, peanut oil, olive oil, phos- pholipids, fatty acids, fatty acid amines, polyoxyethylene or water.
  • the carrier or diluent may include any sustained-release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
  • sustained-release material such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules or tablets, each containing a predetermined amount of the active ingredient, and which may include a suitable excipient. These formulations may be in the form of powder or granules, as a solution or suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion.
  • the preparation may be tabletted, placed in a hard gelatine capsule in powder or pellet form, or it can be in the form of a troche or lozenge.
  • the amount of solid carrier will vary widely, but will usually be from about 25 mg to about 1 g.
  • the preparation may be in the form of a syrup, emulsion, soft gelatine capsule or sterile injectable liquid, such as an aqueous or non-aqueous liquid suspension or solution.
  • a typical tablet which may be prepared by conventional tabletting techniques may contain: Core:
  • HPMC Hydroxypropylmethylcellulose
  • the compounds of the invention may be administered to a mammal, especially a human, in need thereof.
  • mammals include also animals, both domestic animals, e.g. household pets, and non-domestic animals such as wildlife.
  • the pharmaceutical composition of the invention may comprise the compound of the invention in combination with further pharmacologically active substances such as those described in the foregoing.
  • Lipofectamine (Life Technologies, Rockville, MD, U.S.A.) was used for transfection of BHK cells with a GHS-R 1A expression vector (Howard, A. D. et al. (1996), Science 273, 974-977).
  • Receptor binding was assayed as described in Hansen, B. S. et al (1999) Eur.J.Endocrinol. 141 :180-189. Briefly, crude membranes from stably transfected BHK/GHS-R 1A cells were suspended at 0.5 mg protein/ml in homogenization buffer (25 mM Tris-base, 2.5 mM EDTA, 10 mM MgCI 2 and 30 ⁇ g/ml bacitracin).
  • the assay was subsequently incubated at 30°C for 60 minutes, followed by application of the samples to GF/B filters (Whatman, Kent, UK) which had been pre-treated with 0.5% polyethylenimine for 60 minutes.
  • the filters were subsequently washed in 0.9% NaCI and counted using an OptiphaseTM ⁇ iSafe 3' counter (Wallac, Turku, Finland).
  • Binding curves were generated using either the non-linear regression or hyperbolic fit feature of the GraphPadTM Prism software package (GraphPad, San Diego, CA, U.S.A.). Calcium imaging
  • GHSR-expressing cells were cultured in Lab-TekTM chambered coverglasses (Nalge Nunc Int., Naperville, IL, USA). Prior to the experiment, cells were loaded with the Ca 2+ - sensitive dye, Fura2-AM (Molecular Probes Inc., Eugene, OR, U.S.A.), according to standard procedures. The chambers were placed on a temperature-regulated microscope stage and kept at 37°C.
  • Fluorescence images were acquired using the MetaFluorTM software package (Universal Imaging Corporation, West Chester, PA, U.S.A.) together with a Zeiss AxiovertTM 100S inverted microscope (Carl Zeiss, Oberkochen, Germany) and a PrincetonTM MicroMAX-5-1300Y CCD camera (Princeton instruments, Trenton, NJ, U.S.A.).
  • the microscope was also equipped with a 530nm ⁇ 15nm emission filter, a 500nm dichroic mirror (Delta Lys & Optik, Lyngby, Denmark) and a filterwheel (LUDL electronic products, Hawthorne, NY, USA) harbouring 340nm ⁇ 10nm and 380nm+10nm excitation filters (Delta Lys & Optik). Images were acquired every 3 seconds. After acquisition of 12- 14 images, the cells were stimulated with adenosine, MK0677 or other compounds. To test for antagonism the compounds were added together with either adenosine or MK0677.
  • the Fura2 ratio (ratio between the measured intensities of emission at 510 nm following excitation at 340 nm and at 380 nm, respectively) was followed in 50 cells. A normalised ratio was generated for each cell by dividing the Fura2 ratio at time t with the ratio at time zero. The data represented the average normalised Fura2 ratio for 50 cells in a typical experiment. All experiments were repeated at least 4 times (giving similar results).
  • GHS-R 1A (EC 50 ⁇ 50 nM using the Ca assay described above). Binding studies were performed to characterise the binding of adenosine to the GHS-R 1A, and a K D of 87 ⁇ 10 nM was determined. Adenosine was, however, unable to stimulate GH secretion from rat pituitary cells (assay described e.g. in Hansen, B. S. et al (1999) Eur.J.Endocrinol. 141 :180-189).
  • Adenosine does not stimulate growth hormone release, but stimulates feeding
  • GH release was studied in Halothane anaesthetised male Wistar rats after intracerebroventricular (icv) and intravenous (iv) administration of adenosine and also in pentobarbital anaesthetised catheterised female Sprague Dawley (SD) rats after iv administration.
  • Blood samples were obtained from anaesthetised animals before dosing, and either 10 min after dosing or by frequent blood sampling through a catheter up until 45 min after dosing. The plasma was analysed for rat GH.
  • NN703 is described in WO 97/23508, and this compound, together with MK0677 (the latter also being denoted MK677), is also described in, e.g., Drug Discovery Today, vol. 4, No. 11 , November 1999, pp. 497-506.
  • NNC 26-1291 and NNC 26-1187 are growth hormone secretagogues of a non-peptidyl nature and are described in WO 99/58501 and WO 00/26252, respectively.
  • the effect on feeding was tested after icv injections in non-deprived male Wistar rats.
  • the compounds were dissolved in 5 ⁇ l saline and injected in the following doses: 10.0 ⁇ g per rat (NNC 26-1291 ) and 30.0 ⁇ g per rat (NN703 and NNC 26-1187).
  • Food intake was measured in feeding boxes, where standard chow and water were placed on balances and changes in weight continuously registered. Food and water intake was measured for 3 hours after drug injection in the beginning of the light part of the diurnal cycle, when food intake is normally at a very low level. All three compounds increased food intake. The effect of NN703 was moderate, with a food intake at about 3 grams, while NNC 26-1187 and particularly NNC 26-1291 showed stronger effects with food intakes at about 4-5 grams. For comparison, food intake in control animals is normally about 1 gram, and icv administration of 10 ⁇ g porcine neuropeptide Y (NPY), which has a strong effect on food intake, increases food consumption to about 8 grams in this model.
  • NPY porcine neuropeptide Y
  • Ghrelin stimulates feeding, but not GH release, after icv administration
  • Food intake was measured in conscious animals, using feeding boxes. Food and water intake were measured for 3 hours after drug injection during early daytime, when food intake is normally at a very low level.
  • GH release was measured in Halothane-anaesthetised animals from which blood sam- pies were obtained, before dosing and 10 min after dosing, via the orbital plexus. The plasma was analysed for rat GH.
  • Ghrelin administered in this manner produced a significant effect on feeding, compared to vehicle, but did not stimulate GH release.
  • ghrelin administration by the iv route causes stimulation of GH release.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compounds that are ligands for the receptor GHS-R 1A, as well as pharmaceutically acceptable salts thereof, are useful for the manufacture of medicaments for the regulation of food intake.

Description

USE OF COMPOUNDS FOR THE REGULATION OF FOOD INTAKE
FIELD OF THE INVENTION
The present invention relates to the use of a compound that is a ligand for the receptor GHS-R 1 A for the regulation of food intake. The present invention also embraces pharmaceutical compositions comprising these compounds and methods of using the compounds and their pharmaceutical compositions.
BACKGROUND OF THE INVENTION
Stimulation of food intake is important in connection with patients suffering from anorexia due to chronic medical conditions, eating disorders, and other conditions in which excessive weight loss has produced a detrimental effect on the patients' health.
In other situations, suppression of food intake is important. Obesity is a well-known risk factor for the development of many very common diseases such as atherosclerosis, hypertension, Type II diabetes (non-insulin dependent diabetes mellitus (NIDDM)), dyslipi- daemia, coronary heart disease, and osteoarthritis and various malignancies. It also causes considerable problems through reduced mobility and decreased quality of life. The incidence of obesity and thereby also these diseases is increasing throughout the entire industrialised world. Except for exercise, diet and food restriction, no convincing treatment for reducing body weight effectively and acceptably currently exist. However, due to the important effect of obesity as a risk factor in serious and even fatal and common dis- eases, it will be important to find pharmaceutical compounds useful in prevention and treatment of obesity.
Even mild obesity increases the risk of premature death, diabetes, hypertension, atherosclerosis, gallbladder disease and certain types of cancer. In the industrialised western world the prevalence of obesity has increased significantly in the past few decades. Because of the high prevalence of obesity and its health consequences, its prevention and treatment should be a high public health priority. When energy intake exceeds energy expenditure, the excess calories are stored in adipose tissue, and if this net positive balance is prolonged, obesity results, i.e. there are two components to weight balance, and an abnormality on either side (intake or expenditure) can lead to obesity.
It is an object of the present invention to provide compositions that can be used for the regulation of food intake. A further object is to provide compositions that can be used for the treatment of anorexia. A still further object is to provide compositions that can be used for the treatment of excessive weight loss. A further object is to provide compositions that can be used for the treatment of obesity. A still further object is to provide compositions that can be used for the treatment of type II diabetes. Yet another object of the invention is to provide compositions useful in the treatment of wasting, which frequently accompanies ageing as well as various diseases and medical conditions.
SUMMARY OF THE INVENTION
The present invention relates, inter alia, to the use of a compound that is a ligand for the receptor GHS-R 1 A, or pharmaceutically acceptable salts thereof, for the manufacture of a medicament for the regulation of food intake.
DESCRIPTION OF THE INVENTION
Accordingly, the present invention provides the use of a compound that is a ligand for the receptor GHS-R 1A, or pharmaceutically acceptable salts thereof, for the manufacture of a medicament for the regulation of food intake.
A further aspect of the present invention relates to a method for the regulation of food intake, which method comprises administering an effective amount of a compound that is a ligand for the receptor GHS-R 1 A, or pharmaceutically acceptable salts thereof, to a patient in need of such a treatment. A still further aspect of the present invention relates to the use of a compound that is a ligand for the receptor GHS-R 1 A, or pharmaceutically acceptable salts thereof, for the manufacture of a medicament for the regulation of Body Mass Index (BMI).
A further aspect of the present invention relates to the use of a compound that is a ligand for the receptor GHS-R 1 A, or pharmaceutically acceptable salts thereof, for the manufacture of a medicament for the treatment of anorexia.
A still further aspect of the present invention relates to the use of a compound that is a ligand for the receptor GHS-R 1A, or pharmaceutically acceptable salts thereof, for the manufacture of a medicament for the treatment of lack of appetite in children with a growth hormone deficiency.
A further aspect of the present invention relates to the use of a compound that is a ligand for the receptor GHS-R 1A, or pharmaceutically acceptable salts thereof, for the manufacture of a medicament for the treatment of obesity.
A still further aspect of the present invention relates to the use of a compound that is a ligand for the receptor GHS-R 1 A, or pharmaceutically acceptable salts thereof, for the manufacture of a medicament for the treatment of Type II diabetes.
A further aspect of the present invention relates to the use of a compound that is a ligand for the receptor GHS-R 1A, or pharmaceutically acceptable salts thereof, for the manufacture of a medicament for the treatment of wasting associated with various diseases or conditions, e.g. wasting associated with AIDS, chronic liver disease, chronic obstructive pulmonary disease (COPD) or respiratory insufficiency in general, as well as wasting associated with bone fractures or with ageing. Wasting, which involves a progressive loss of body mass, including muscle mass, is normally attributable to a catabolic state of metabolism, and is frequently difficult to reverse by purely dietary means.
In one embodiment of the present invention the receptor GHS-R 1A is the human GHS-R 1A receptor. In another embodiment the medicament is for humans. In a still further embodiment of the invention the compound does not induce a therapeutically effective growth hormone release at the therapeutic dose of the compound.
In a further embodiment of the invention the medicament is a non-injectable medicament. In a still further embodiment the medicament is an oral medicament.
The receptor GHS-R 1 A (the growth hormone secretagogue receptor type 1 A) is described by Howard, A. D. et al. (1996) in Science 273, 974-977.
The binding of a compound to the receptor GHS-R 1A can, e.g., be measured by the use of the assays as described in Example 1 herein.
In one embodiment of the invention the ligand has a potency (EC50) on the GHS-R 1A of less than 500 nM. In another embodiment the ligand has a potency (EC50) on the GHS-R 1A of less than 100 nM.
In a further embodiment the binding constant (KD) of the ligand is less than 500 nM. In a still further embodiment the binding constant (KD) of the ligand is less than 100 nM.
In yet another embodiment of the invention the ligand is an agonist for the receptor GHS- R 1A. In another embodiment of the invention the ligand is an antagonist for the receptor GHS-R 1A.
In a still further embodiment the compound employed in accordance with the invention is adenosine. In a further embodiment the compound is ghrelin or a peptide homologous thereto. Ghrelin is described by Kojima in Nature (1999), vol. 402, 656-660.
Peptides homologous to ghrelin are peptides which have an amino acid sequence which has a degree of identity to ghrelin of at least about 70%, preferably at least about 80%, more preferably at least about 90%, even more preferably at least about 95%, and most preferably at least about 97%, and which qualitatively retain the activity as a ligand for the receptor GHS-R 1A. The degree of identity between two or more amino acid sequences may be determined by means of computer programs known in the art, such as GAP provided in the GCG program package (Needleman and Wunsch, 1970, Journal of Molecular Biology 48:443-453). For the purposes of determining the degree of identity between two amino acid sequences for the present invention, GAP is used with the following settings: GAP creation penalty of 3.0 and GAP extension penalty of 0.1.
Within the context of the present invention, "a therapeutically effective growth hormone release" is to be understood as a growth hormone release which would have a therapeutic effect in treatment of the specific indication, e.g. regulation of food intake.
The therapeutic dose of the compound will depend upon the frequency and mode of administration, the sex, age, weight and general condition of the subject treated, the nature and severity of the condition treated and any concomitant diseases to be treated, and other factors evident to those skilled in the art. In one embodiment, the effective amount of the compound is in the range from about 0.05 to about 2000 mg, preferably from about 0,1 mg to about 1000 mg, and especially from about 0.5 to about 500 mg per day.
The term obesity implies an excess of adipose tissue. In this context, obesity is best viewed as any degree of excess adiposity that imparts a health risk. The distinction between normal and obese individuals can only be approximated, but the health risk im- parted by obesity is probably a continuum with increasing adiposity. However, in the context of the present invention, individuals with a Body Mass Index (BMI, defined as the body weight of a human individual in kilograms divided by the square of the height of that individual in meters) above 25 are to be regarded as obese.
The present invention also encompasses pharmaceutically acceptable salts of the present compounds. Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable metal salts, ammonium salts and alkylated ammonium salts. Acid addition salts include salts of inorganic acids as well as organic acids. Representative examples of suitable inorganic acids include hydrochloric, hydrobromic, hydriodic, phosphoric, sulpfuric and nitric acids and the like. Representative examples of suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methanesulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, ethylenediaminetetraacetic (EDTA), p-aminobenzoic, glutamic, benzenesulfonic and p- toluenesulfonic acids and the like. Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in J. Pharm. Sci. 1977, 66, 2, which is incorporated herein by reference. Examples of metal salts include lithium, sodium, potassium and magnesium salts and the like. Examples of ammonium and alkylated ammonium salts include ammonium, methylammonium, dimethylammonium, trimethylammonium, ethylammonium, hydroxyethylammonium, diethylammonium, butylammonium and tetramethylammonium salts and the like.
Also included within the scope of compounds or pharmaceutically acceptable acid addition salts thereof in the context of the present invention are any hydrates (hydrated forms) thereof.
Within the context of the present invention, a "ligand for the receptor GHS-R 1A" is understood to refer to any compound which has affinity to the receptor GHS-R 1 A as measured by the method as described in Example 1 herein.
Within the context of the present invention, treatment is to be understood as treatment and/or prevention.
In a still further aspect, the invention relates to a pharmaceutical composition comprising, as an active ingredient, a compound as defined above or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier.
In a further aspect of the invention the present compounds may be administered in combination with further pharmacologically active substances, e.g. an antidiabetic agent or other pharmacologically active material, including other compounds for the treatment and/or prevention of insulin resistance and diseases wherein insulin resistance is the pathophysiological mechanism.
Furthermore, the compounds according to the invention may be administered in combination with antiobesity agents or appetite-regulating agents. A still further aspect of the present invention is a method of identifying compounds for the regulation of food intake, characterised by screening out compounds that act as ligands for the receptor GHS-R 1 A. A further aspect of the present invention relates to a compound identified by or identifiable by this method.
PHARMACEUTICAL COMPOSITION
The compounds of the invention may be administered alone or in combination with pharmaceutically acceptable carriers or excipients, in either single or multiple doses. The pharmaceutical compositions according to the invention may be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 19th Edition, Gennaro, Ed., Mack
Publishing Co., Easton, PA, 1995.
The pharmaceutical compositions may be specifically formulated for administration by any suitable route such as the oral, rectal, nasal, pulmonary, topical (including buccal and sublingual), transdermal, intracisternal, intraperitoneal, vaginal and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous and intradermal) route, the oral route being preferred. It will be appreciated that the choice of route will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated and the active ingredient chosen.
Pharmaceutical compositions for oral administration include solid dosage forms such as capsules, tablets, dragees, pills, lozenges, powders and granules. Where appropriate, they can be prepared with coatings, such as enteric coatings, or they can be formulated so as to provide controlled release of the active ingredient, such as sustained or prolonged release according to methods well known in the art.
Liquid dosage forms for oral administration include solutions, emulsions, suspensions, syrups and elixirs.
Pharmaceutical compositions for parenteral administration include sterile aqueous and non-aqueous injectable solutions, dispersions, suspensions or emulsions, as well as ster- ile powders to be reconstituted in sterile injectable solutions or dispersions prior to use. Depot injectable formulations are also contemplated as being within the scope of the present invention.
Other suitable administration forms include suppositories, sprays, ointments, cremes, gels, inhalants, dermal patches, implants etc.
A typical oral dosage of a compound employed according to the invention is in the range of from about 0.0001 to about 100 mg/kg body weight per day, preferably from about 0.001 to about 10 mg/kg body weight per day, and more preferably from about 0.01 to about 1 mg/kg body weight per day, administered in one or more doses, such as 1 to 3 doses.
The formulations may conveniently be presented in unit dosage form by methods known to those skilled in the art. A typical unit dosage form for oral administration one or more times per day, such as 1 to 3 times per day, may contain from about 0.05 to about 2000 mg, preferably from about 0.1 to about 500 mg, and more preferably from about 0.5 mg to about 200 mg of a compound employed according to the invention.
For parenteral routes, such as intravenous, intrathecal, intramuscular and similar routes of administration, doses are typically of the order of about half the dose employed for oral administration.
The compounds of this invention are generally utilized as the free substance or as a phar- maceutically acceptable salt thereof. One example is an acid addition salt of a compound having a free base functionality. When a compound of the invention contains a free base functionality, such salts are suitably prepared in a conventional manner by treating a solution or suspension of the free base form of the compound with, typically, one equivalent (chemical equivalent, i.e. acid-base equivalent) of a pharmaceutically acceptable acid, for example an inorganic or organic acid chosen among the representative examples thereof mentioned above. Physiologically acceptable salts of a compound with a hydroxy group include the anion of said compound in combination with a suitable cation, such as sodium or ammonium ion. For parenteral administration, solutions of the present compounds in sterile aqueous solution, aqueous propylene glycol or sesame or peanut oil may be employed. Such aqueous solutions should be suitably buffered if necessary, and the liquid diluent first rendered iso- tonic with sufficient saline or glucose. The aqueous solutions are particularly suitable for in- travenous, intramuscular, subcutaneous and intraperitoneal administration. The sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.
Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solution and various organic solvents. Examples of solid carriers are lactose, terra alba, sucrose, cyclodextrin, talc, gelatine, agar, pectin, acacia, magnesium stearate, stearic acid or lower alkyl ethers of cellulose. Examples of liquid carriers are syrup, peanut oil, olive oil, phos- pholipids, fatty acids, fatty acid amines, polyoxyethylene or water. Similarly, the carrier or diluent may include any sustained-release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax. The pharmaceutical compositions formed by combining the compounds of the invention and the pharmaceutically acceptable carriers are then readily administered in a variety of dosage forms suitable for the disclosed routes of administration. The formulations may conveniently be presented in unit dosage form by methods known in the art of pharmacy.
Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules or tablets, each containing a predetermined amount of the active ingredient, and which may include a suitable excipient. These formulations may be in the form of powder or granules, as a solution or suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion.
If a solid carrier is used for oral administration, the preparation may be tabletted, placed in a hard gelatine capsule in powder or pellet form, or it can be in the form of a troche or lozenge. The amount of solid carrier will vary widely, but will usually be from about 25 mg to about 1 g. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatine capsule or sterile injectable liquid, such as an aqueous or non-aqueous liquid suspension or solution.
A typical tablet which may be prepared by conventional tabletting techniques may contain: Core:
Active compound (as free compound or salt thereof) 5 mg
Colloidal silicon dioxide (Aerosil™) 1.5 mg
Cellulose, microcryst. (Avicel™) 70 mg Modified cellulose gum (Ac-Di-Sol™) 7.5 mg
Magnesium stearate q.s.
Coating:
Hydroxypropylmethylcellulose (HPMC) approx. 9 mg *Mywacett™ 9-40 T approx. 0.9 mg
*Acylated monoglyceride used as plasticizer for film coating.
The compounds of the invention may be administered to a mammal, especially a human, in need thereof. Such mammals include also animals, both domestic animals, e.g. household pets, and non-domestic animals such as wildlife.
If desired, the pharmaceutical composition of the invention may comprise the compound of the invention in combination with further pharmacologically active substances such as those described in the foregoing.
The present invention is further illustrated by the following examples which, however, are not to be construed as limiting the scope of protection.
EXAMPLES
Example 1
Identification of ligands for the receptor GHS-R 1 A
Transfection
Lipofectamine (Life Technologies, Rockville, MD, U.S.A.) was used for transfection of BHK cells with a GHS-R 1A expression vector (Howard, A. D. et al. (1996), Science 273, 974-977).
Receptor binding assay
Receptor binding was assayed as described in Hansen, B. S. et al (1999) Eur.J.Endocrinol. 141 :180-189. Briefly, crude membranes from stably transfected BHK/GHS-R 1A cells were suspended at 0.5 mg protein/ml in homogenization buffer (25 mM Tris-base, 2.5 mM EDTA, 10 mM MgCI2 and 30 μg/ml bacitracin). In a microtiter plate 10 μl membrane suspension was combined with either 35S-labelled MK0677 (see Example 4) (Amersham Pharmacia Biotech, Essex, UK) or 2-3H-adenosine (Amersham) as well as binding buffer (2.5 mM Tris-base, 2.5 r M EDTA and 10 mM MgCI2) to a total volume of 250 μl. Non-specific binding was determined by adding 10 μM MK0677 (see Example 4) or 10 μM adenosine to the assay. The assay was subsequently incubated at 30°C for 60 minutes, followed by application of the samples to GF/B filters (Whatman, Kent, UK) which had been pre-treated with 0.5% polyethylenimine for 60 minutes. The filters were subsequently washed in 0.9% NaCI and counted using an Optiphase™ ΗiSafe 3' counter (Wallac, Turku, Finland).
To test for compounds that can compete with binding of either 35S-MK0677 or 3H- adenosine to the GHS-R 1A, different concentrations (0.001 nmol/l to 10 μmol/l) of the compound were added to the incubation described above.
Specific binding was determined as the difference between total binding and non-specific binding (binding in the presence of 10 μM unlabelled ligand). Binding curves were generated using either the non-linear regression or hyperbolic fit feature of the GraphPad™ Prism software package (GraphPad, San Diego, CA, U.S.A.). Calcium imaging
To test for agonism or antagonism of the compounds that can compete with the binding of the radiolabelled ligands in the above receptor assay, a functional assay based on stimulation of the release of Ca++ via the GHS-R was developed.
GHSR-expressing cells were cultured in Lab-Tek™ chambered coverglasses (Nalge Nunc Int., Naperville, IL, USA). Prior to the experiment, cells were loaded with the Ca2+- sensitive dye, Fura2-AM (Molecular Probes Inc., Eugene, OR, U.S.A.), according to standard procedures. The chambers were placed on a temperature-regulated microscope stage and kept at 37°C. Fluorescence images were acquired using the MetaFluor™ software package (Universal Imaging Corporation, West Chester, PA, U.S.A.) together with a Zeiss Axiovert™ 100S inverted microscope (Carl Zeiss, Oberkochen, Germany) and a Princeton™ MicroMAX-5-1300Y CCD camera (Princeton instruments, Trenton, NJ, U.S.A.). The microscope was also equipped with a 530nm±15nm emission filter, a 500nm dichroic mirror (Delta Lys & Optik, Lyngby, Denmark) and a filterwheel (LUDL electronic products, Hawthorne, NY, USA) harbouring 340nm±10nm and 380nm+10nm excitation filters (Delta Lys & Optik). Images were acquired every 3 seconds. After acquisition of 12- 14 images, the cells were stimulated with adenosine, MK0677 or other compounds. To test for antagonism the compounds were added together with either adenosine or MK0677. In each experiment the Fura2 ratio (ratio between the measured intensities of emission at 510 nm following excitation at 340 nm and at 380 nm, respectively) was followed in 50 cells. A normalised ratio was generated for each cell by dividing the Fura2 ratio at time t with the ratio at time zero. The data represented the average normalised Fura2 ratio for 50 cells in a typical experiment. All experiments were repeated at least 4 times (giving similar results).
Example 2
Identification of adenosine as a ligand for the receptor GHS-R 1A
The methods of example 1 were used. Adenosine was found to be a potent ligand for the
GHS-R 1A (EC50 ~ 50 nM using the Ca assay described above). Binding studies were performed to characterise the binding of adenosine to the GHS-R 1A, and a KD of 87 ± 10 nM was determined. Adenosine was, however, unable to stimulate GH secretion from rat pituitary cells (assay described e.g. in Hansen, B. S. et al (1999) Eur.J.Endocrinol. 141 :180-189).
Example 3
Adenosine does not stimulate growth hormone release, but stimulates feeding
The effect on GH release was studied in Halothane anaesthetised male Wistar rats after intracerebroventricular (icv) and intravenous (iv) administration of adenosine and also in pentobarbital anaesthetised catheterised female Sprague Dawley (SD) rats after iv administration. Vehicle or adenosine was given to groups of rats (n=4-6) in the following doses: 10 μg/rat and 100 μg/rat icv dissolved in 5 μl saline, 1 mg/kg iv and also 10 mg/kg iv to the SD rats. Blood samples were obtained from anaesthetised animals before dosing, and either 10 min after dosing or by frequent blood sampling through a catheter up until 45 min after dosing. The plasma was analysed for rat GH.
The effect on feeding was studied in conscious non-deprived male Wistar rats (n=7-10) after icv dosing of vehicle or adenosine (1 μg/rat and 10 μg/rat in 5 μl saline). Food intake was measured in feeding boxes with standard chow and water placed on balances con- nected to a computer. Changes in weight of chow and water were continuously registered. Food and water intake were measured for 3 hours after drug injection during early daytime, when food intake is normally at a very low level.
The results showed that adenosine did not stimulate GH release in any of the given doses, neither by the icv nor the iv route of administration.
With respect to the orexigenic effect of adenosine, there was no effect after 1 μg/rat, but food intake was significantly increased compared to the vehicle control group after injection of 10 μg/rat adenosine icv.
Example 4
Correlation between GHS-R 1A binding affinity and the effect on food intake The compounds used were characterised by showing equipotency with respect to in vitro GH release from primary rat somatotrophs, although they displayed significantly different binding affinity to the GHS-R 1A.
The following compounds (structures shown below) were employed: NNC 26-1291 , with a high binding affinity to the receptor similar to that of MK0677 (K, = 0.4 ± 0.06 nM), NNC 26-1187 with an intermediate binding affinity (K, = 22.2 ± 7 nM), and NN703 displaying a weak binding affinity (K, = 112 ± 29 nM).
NN703 is described in WO 97/23508, and this compound, together with MK0677 (the latter also being denoted MK677), is also described in, e.g., Drug Discovery Today, vol. 4, No. 11 , November 1999, pp. 497-506. NNC 26-1291 and NNC 26-1187 are growth hormone secretagogues of a non-peptidyl nature and are described in WO 99/58501 and WO 00/26252, respectively.
The effect on feeding was tested after icv injections in non-deprived male Wistar rats. The compounds were dissolved in 5 μl saline and injected in the following doses: 10.0 μg per rat (NNC 26-1291 ) and 30.0 μg per rat (NN703 and NNC 26-1187).
Food intake was measured in feeding boxes, where standard chow and water were placed on balances and changes in weight continuously registered. Food and water intake was measured for 3 hours after drug injection in the beginning of the light part of the diurnal cycle, when food intake is normally at a very low level. All three compounds increased food intake. The effect of NN703 was moderate, with a food intake at about 3 grams, while NNC 26-1187 and particularly NNC 26-1291 showed stronger effects with food intakes at about 4-5 grams. For comparison, food intake in control animals is normally about 1 gram, and icv administration of 10μg porcine neuropeptide Y (NPY), which has a strong effect on food intake, increases food consumption to about 8 grams in this model.
The compounds employed were as follows: NNC 26-1291
Figure imgf000016_0001
NNC 26-1187
Figure imgf000016_0002
Example 5
Ghrelin stimulates feeding, but not GH release, after icv administration
Non-deprived male Wistar rats (n=6-10) were used for the study, dosed with vehicle or with ghrelin at 10 μg/rat icv dissolved in 5 μl saline. Food intake was measured in conscious animals, using feeding boxes. Food and water intake were measured for 3 hours after drug injection during early daytime, when food intake is normally at a very low level. GH release was measured in Halothane-anaesthetised animals from which blood sam- pies were obtained, before dosing and 10 min after dosing, via the orbital plexus. The plasma was analysed for rat GH.
Ghrelin administered in this manner (icv administration) produced a significant effect on feeding, compared to vehicle, but did not stimulate GH release. In contrast, it is known that ghrelin administration by the iv route causes stimulation of GH release.

Claims

1. The use of a compound that is a ligand for the receptor GHS-R 1A, or pharmaceutically acceptable salts thereof, for the manufacture of a medicament for the regulation of food intake.
2. The use according to claim 1 , wherein the compound does not induce a therapeutic effective growth hormone release at the therapeutic dose of the compound.
3. The use according to claims 1 or 2, wherein the medicament is for humans.
4. The use according to any one of claims 1-3, wherein the medicament is a non- injectable medicament.
5. The use according to any one of claims 1-4, wherein the ligand is an agonist.
6. The use according to any one of claims 1-4, wherein the ligand is an antagonist.
7. The use according to any one of claims 1-5, wherein the compound is selected from the group consisting of adenosine, ghrelin and ghrelin homologues.
8. A method for the regulation of food intake, which method comprises administering an effective amount of a compound as defined in any one of claims 1 , 2 or 5-7 to a patient in need of such a treatment.
9. A method for identifying compounds for the regulation of food intake, characterised by screening out compounds that act as ligands for the GHS receptor type 1 A (GHS-R 1A).
10. Compounds identified by a method according to claim 9.
11. The use of a compound as defined in any one of claims 1 , 2 or 5-7 for the manufacture of a medicament for the regulation of Body Mass Index (BMI).
12. The use of a compound as defined in any one of claims 1 , 2 or 5-7 for the manufacture of a medicament for the treatment of anorexia.
13. The use of a compound as defined in any one of claims 1 , 2 or 5-7 for the manufacture of a medicament for the treatment of lack of appetite in children with a growth hormone deficiency.
14. The use of a compound as defined in any one of claims 1 , 2 or 5-7 for the manufacture of a medicament for the treatment of obesity.
15. The use of a compound as defined in any one of claims 1 , 2 or 5-7 for the manufacture of a medicament for the treatment of Type II diabetes.
16. The use of a compound according to any one of claims 1 ,2 or 5-7 for the manufacture of a medicament for the treatment of wasting associated with AIDS.
17. A pharmaceutical composition comprising, as an active ingredient, a compound as defined in any one of claims 1 , 2 or 5-7 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
18. A composition according to claim 17 in unit dosage form, comprising from about 0.05 to about 2000 mg, preferably from about 0.1 to about 500 mg of a compound as defined in any one of claims 1 , 2 or 5-7 or a pharmaceutically acceptable salt thereof.
19. A pharmaceutical composition for the regulation of food intake, the composition comprising, as an active ingredient, a compound as defined in any one of claims 1 , 2 or 5- 7 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
20. A pharmaceutical composition according to any one of the claims 17-19 for oral, nasal, transdermal, pulmonal or parenteral administration.
PCT/DK2001/000064 2000-02-01 2001-01-29 Use of compounds for the regulation of food intake WO2001056592A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001228325A AU2001228325A1 (en) 2000-02-01 2001-01-29 Use of compounds for the regulation of food intake

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200000161 2000-02-01
DKPA200000161 2000-02-01
DKPA200001107 2000-07-17
DKPA200001107 2000-07-17

Publications (1)

Publication Number Publication Date
WO2001056592A1 true WO2001056592A1 (en) 2001-08-09

Family

ID=26068754

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2001/000064 WO2001056592A1 (en) 2000-02-01 2001-01-29 Use of compounds for the regulation of food intake

Country Status (2)

Country Link
AU (1) AU2001228325A1 (en)
WO (1) WO2001056592A1 (en)

Cited By (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060472A1 (en) * 2001-01-31 2002-08-08 Chugai Seiyaku Kabushiki Kaisha Remedies for hyponutrition status
WO2003051389A2 (en) 2001-12-18 2003-06-26 Theratechnologies Inc. Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
WO2004002986A2 (en) 2002-06-28 2004-01-08 Banyu Pharmaceutical Co., Ltd. Novel benzimidazole derivatives
EP1407779A1 (en) * 2002-10-10 2004-04-14 Gastrotech A/S Use of ghrelin for treating low body weight and body fat in gastrectomized individuals
WO2004056869A1 (en) * 2002-12-20 2004-07-08 7Tm Pharma A/S Ghrelin receptor inverse agonist for regulation of feeding behaviours
WO2004084943A1 (en) * 2003-03-19 2004-10-07 Beth Israel Deaconess Medical Center, Inc Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
WO2005014032A2 (en) * 2003-08-06 2005-02-17 Gastrotech Pharma A/S Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
WO2005028438A1 (en) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
EP1541171A1 (en) * 2002-07-05 2005-06-15 Chugai Seiyaku Kabushiki Kaisha Therapeutics for diabetes mellitus
WO2005114180A2 (en) * 2004-05-14 2005-12-01 Novo Nordisk A/S Functional ghs-r antagonists
EP1632244A1 (en) * 2003-04-30 2006-03-08 Kenji Kangawa Preventives or remedies for hepatopathy
WO2006045313A2 (en) * 2004-10-27 2006-05-04 Gastrotech Pharma A/S Uses of secretagogues for treatment of organ transplant patients
WO2006045319A2 (en) * 2004-10-27 2006-05-04 Gastrotech Pharma A/S Uses of growth hormone secretagogues in the treatment of individuals suffering from renal and/or liver failure
WO2006129826A1 (en) 2005-05-30 2006-12-07 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
WO2007018248A1 (en) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone compound
WO2007024004A1 (en) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
WO2007029847A1 (en) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. Bicyclic aromatic substituted pyridone derivative
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2007049798A1 (en) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
WO2007055418A1 (en) 2005-11-10 2007-05-18 Banyu Pharmaceutical Co., Ltd. Aza-substituted spiro derivative
WO2007095347A2 (en) * 2006-02-13 2007-08-23 The Gov. Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Methods and compositions related to ghs-r antagonists
WO2008038692A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
JP2008509930A (en) * 2004-08-12 2008-04-03 サファイア セラピューティクス インコーポレイテッド A method of stimulating gastrointestinal motility using growth hormone secretagogues
WO2008120653A1 (en) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
EP2088154A1 (en) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2009110510A1 (en) 2008-03-06 2009-09-11 萬有製薬株式会社 Alkylaminopyridine derivative
WO2009119726A1 (en) 2008-03-28 2009-10-01 萬有製薬株式会社 Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
WO2009154132A1 (en) 2008-06-19 2009-12-23 萬有製薬株式会社 Spirodiamine-diarylketoxime derivative
WO2010013595A1 (en) 2008-07-30 2010-02-04 萬有製薬株式会社 (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
US7666833B2 (en) 2001-12-18 2010-02-23 Alizé Pharma SAS Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051236A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US7803768B2 (en) 2005-02-23 2010-09-28 Kyoto University Method for treatment of hyperglycemia in a subject in need thereof
US7825090B2 (en) 2003-10-24 2010-11-02 Alizé Pharma SAS Use of ghrelin and unacylated ghrelin compositions for treating insulin resistance
EP2298337A2 (en) 2003-12-09 2011-03-23 Novo Nordisk A/S Regulation of food preference using GLP-1 agonists
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
EP2316446A1 (en) 2004-06-11 2011-05-04 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
WO2011053821A1 (en) 2009-10-30 2011-05-05 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
WO2011069038A2 (en) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2332526A2 (en) 2005-10-21 2011-06-15 Novartis AG Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8222217B2 (en) 2007-05-31 2012-07-17 Alize Pharma Sas Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders
WO2012116145A1 (en) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US8318664B2 (en) 2007-05-31 2012-11-27 Alize Pharma Sas Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity
WO2013059222A1 (en) 2011-10-19 2013-04-25 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-nitrile orexin receptor antagonists
US8476408B2 (en) 2008-06-13 2013-07-02 Alize Pharma Sas Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP2698157A1 (en) 2006-09-22 2014-02-19 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2810951A2 (en) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051725A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2016030534A1 (en) 2014-08-29 2016-03-03 Tes Pharma S.R.L. INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
EP2998314A1 (en) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US9550821B2 (en) 2011-12-15 2017-01-24 Alize Pharma Sas Modulation of ghrelin levels and ghrelin/unacylated ghrelin ratio using unacylated ghrelin
EP3241839A1 (en) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2018069532A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
WO2020104456A1 (en) 2018-11-20 2020-05-28 Tes Pharma S.R.L INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
WO2020167706A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
WO2022040070A1 (en) 2020-08-18 2022-02-24 Merck Sharp & Dohme Corp. Bicycloheptane pyrrolidine orexin receptor agonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880783A (en) * 1986-10-06 1989-11-14 University Of Virginia Alumnia Patents Foundation Use of adenosine, hypoxanthine and ribose-containing solution for improved protection of the heart during surgery

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880783A (en) * 1986-10-06 1989-11-14 University Of Virginia Alumnia Patents Foundation Use of adenosine, hypoxanthine and ribose-containing solution for improved protection of the heart during surgery

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Adenosine", 1999, MERCK & CO INC, WHITEHOUSE STATION NJ US, XP002901679 *
MASAMITSU NAKAZATO ET AL: "A role for ghrelin in the central regulation of feeding", NATURE, vol. 409, 11 January 2001 (2001-01-11), pages 194 - 198, XP002901678 *

Cited By (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060472A1 (en) * 2001-01-31 2002-08-08 Chugai Seiyaku Kabushiki Kaisha Remedies for hyponutrition status
US7666833B2 (en) 2001-12-18 2010-02-23 Alizé Pharma SAS Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
WO2003051389A2 (en) 2001-12-18 2003-06-26 Theratechnologies Inc. Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
US8071368B2 (en) 2001-12-18 2011-12-06 Alizé Pharma SAS Methods for promoting growth and survival of insulin-secreting cells
US7485620B2 (en) 2001-12-18 2009-02-03 Alizé Pharma SAS Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
WO2004002986A2 (en) 2002-06-28 2004-01-08 Banyu Pharmaceutical Co., Ltd. Novel benzimidazole derivatives
EP1541171A1 (en) * 2002-07-05 2005-06-15 Chugai Seiyaku Kabushiki Kaisha Therapeutics for diabetes mellitus
EP1541171A4 (en) * 2002-07-05 2008-04-09 Chugai Pharmaceutical Co Ltd Therapeutics for diabetes mellitus
US7592305B2 (en) 2002-10-10 2009-09-22 Gastrotech Pharma A/S Use of ghrelin for treating malnutrition in gastrectomized individuals
EP1407779A1 (en) * 2002-10-10 2004-04-14 Gastrotech A/S Use of ghrelin for treating low body weight and body fat in gastrectomized individuals
WO2004032952A1 (en) * 2002-10-10 2004-04-22 Gastrotech Pharma A/S Use of ghrelin for treating malnutrition in gastrectomized individuals
WO2004056869A1 (en) * 2002-12-20 2004-07-08 7Tm Pharma A/S Ghrelin receptor inverse agonist for regulation of feeding behaviours
WO2004084943A1 (en) * 2003-03-19 2004-10-07 Beth Israel Deaconess Medical Center, Inc Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
EP1632244A1 (en) * 2003-04-30 2006-03-08 Kenji Kangawa Preventives or remedies for hepatopathy
US10653637B2 (en) 2003-04-30 2020-05-19 Kenji Kangawa Preventives or remedies for hepatopathy
EP1632244A4 (en) * 2003-04-30 2009-11-11 Kenji Kangawa Preventives or remedies for hepatopathy
WO2005014032A2 (en) * 2003-08-06 2005-02-17 Gastrotech Pharma A/S Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
JP2007523048A (en) * 2003-08-06 2007-08-16 ガストロテック・ファルマ・アクティーゼルスカブ Use of secretagogues
WO2005014032A3 (en) * 2003-08-06 2005-03-17 Gastrotech Pharma As Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
WO2005028438A1 (en) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
US7825090B2 (en) 2003-10-24 2010-11-02 Alizé Pharma SAS Use of ghrelin and unacylated ghrelin compositions for treating insulin resistance
EP2298337A2 (en) 2003-12-09 2011-03-23 Novo Nordisk A/S Regulation of food preference using GLP-1 agonists
EP2088154A1 (en) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
WO2005114180A2 (en) * 2004-05-14 2005-12-01 Novo Nordisk A/S Functional ghs-r antagonists
WO2005114180A3 (en) * 2004-05-14 2006-04-13 Novo Nordisk As Functional ghs-r antagonists
EP2316446A1 (en) 2004-06-11 2011-05-04 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
JP2008509930A (en) * 2004-08-12 2008-04-03 サファイア セラピューティクス インコーポレイテッド A method of stimulating gastrointestinal motility using growth hormone secretagogues
WO2006045313A2 (en) * 2004-10-27 2006-05-04 Gastrotech Pharma A/S Uses of secretagogues for treatment of organ transplant patients
WO2006045319A3 (en) * 2004-10-27 2006-09-28 Gastrotech Pharma As Uses of growth hormone secretagogues in the treatment of individuals suffering from renal and/or liver failure
WO2006045313A3 (en) * 2004-10-27 2006-08-03 Gastrotech Pharma As Uses of secretagogues for treatment of organ transplant patients
WO2006045319A2 (en) * 2004-10-27 2006-05-04 Gastrotech Pharma A/S Uses of growth hormone secretagogues in the treatment of individuals suffering from renal and/or liver failure
US7803768B2 (en) 2005-02-23 2010-09-28 Kyoto University Method for treatment of hyperglycemia in a subject in need thereof
WO2006129826A1 (en) 2005-05-30 2006-12-07 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
WO2007018248A1 (en) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone compound
WO2007024004A1 (en) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
WO2007029847A1 (en) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. Bicyclic aromatic substituted pyridone derivative
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
EP2332526A2 (en) 2005-10-21 2011-06-15 Novartis AG Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
WO2007049798A1 (en) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
WO2007055418A1 (en) 2005-11-10 2007-05-18 Banyu Pharmaceutical Co., Ltd. Aza-substituted spiro derivative
WO2007095347A2 (en) * 2006-02-13 2007-08-23 The Gov. Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Methods and compositions related to ghs-r antagonists
WO2007095347A3 (en) * 2006-02-13 2007-12-21 Us Gov Health & Human Serv Methods and compositions related to ghs-r antagonists
EP2946778A1 (en) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
EP2698157A1 (en) 2006-09-22 2014-02-19 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2008038692A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
WO2008120653A1 (en) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
US8222217B2 (en) 2007-05-31 2012-07-17 Alize Pharma Sas Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders
US8318664B2 (en) 2007-05-31 2012-11-27 Alize Pharma Sas Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity
EP2998314A1 (en) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009110510A1 (en) 2008-03-06 2009-09-11 萬有製薬株式会社 Alkylaminopyridine derivative
WO2009119726A1 (en) 2008-03-28 2009-10-01 萬有製薬株式会社 Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
EP2810951A2 (en) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8476408B2 (en) 2008-06-13 2013-07-02 Alize Pharma Sas Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
WO2009154132A1 (en) 2008-06-19 2009-12-23 萬有製薬株式会社 Spirodiamine-diarylketoxime derivative
EP3241839A1 (en) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010013595A1 (en) 2008-07-30 2010-02-04 萬有製薬株式会社 (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051236A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011053821A1 (en) 2009-10-30 2011-05-05 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
EP2923706A1 (en) 2009-12-03 2015-09-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia
WO2011069038A2 (en) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP3243385A1 (en) 2011-02-25 2017-11-15 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2012116145A1 (en) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2013059222A1 (en) 2011-10-19 2013-04-25 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-nitrile orexin receptor antagonists
US9550821B2 (en) 2011-12-15 2017-01-24 Alize Pharma Sas Modulation of ghrelin levels and ghrelin/unacylated ghrelin ratio using unacylated ghrelin
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
EP3708179A1 (en) 2012-03-15 2020-09-16 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
EP4309673A2 (en) 2012-03-15 2024-01-24 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051725A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9708272B2 (en) 2014-08-29 2017-07-18 Tes Pharma S.R.L. Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase
US10513499B2 (en) 2014-08-29 2019-12-24 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2016030534A1 (en) 2014-08-29 2016-03-03 Tes Pharma S.R.L. INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
US11254644B2 (en) 2014-08-29 2022-02-22 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018069532A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
WO2020104456A1 (en) 2018-11-20 2020-05-28 Tes Pharma S.R.L INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
WO2020167706A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
WO2022040070A1 (en) 2020-08-18 2022-02-24 Merck Sharp & Dohme Corp. Bicycloheptane pyrrolidine orexin receptor agonists

Also Published As

Publication number Publication date
AU2001228325A1 (en) 2001-08-14

Similar Documents

Publication Publication Date Title
WO2001056592A1 (en) Use of compounds for the regulation of food intake
US7994329B2 (en) Growth hormone secretagogue receptor type 1A agonists
US20070060609A1 (en) Identification and Use of Growth Hormone Secretagogue Receptor Type 1A Antagonists
TWI735917B (en) Gip/glp1 co-agonist compounds
TWI744579B (en) Incretin analogs and uses thereof
Smith et al. Peptidomimetic regulation of growth hormone secretion
US7928058B2 (en) Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition
EP1104438B1 (en) Novel anti-diabetic peptides
US8481489B2 (en) GH secretagogues and uses thereof
AU2012311484A1 (en) Novel glucagon analogues
AU2005297366B2 (en) GH secretagogues and uses thereof
AU2021211451B2 (en) GIP/GLP1 co-agonist compounds
US11278595B2 (en) Peptides comprising non-natural amino acids and methods of making and using the same
AU2020408139B2 (en) Incretin analogs and uses thereof
JP2002522355A (en) New mixed amylin active compounds
AU705984B2 (en) Corticotropin-releasing factor-binding protein inhibitors and their use
WO1996002569A9 (en) Corticotropin-releasing factor-binding-protein inhibitors and their use
WO1996002569A1 (en) Corticotropin-releasing factor-binding-protein inhibitors and their use
MXPA96004802A (en) Treatment of cardiac failure congest

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP